Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation -Joint Ventures, Innovation, Growth and Restructuring

Frontier Pharma Obesity - Identifying and Commercializing

First-in-Class Innovation - Market study and key country

analysis research report

Obesity is a major growing health concern around the world. In most markets, a

person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms

per square meter (kg/m2), calculated by dividing body mass in kilograms by

height in meters squared. With the global prevalence continuing to rise, the

disease has placed significant burden on healthcare expenditure, as it is also a

major risk factor for cardiovascular diseases, diabetes and cancer.

Get sample report at @ : https://marketreportscenter.com/requestsample/5223

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to

improve weight loss in order to significantly reduce obesity-associated health risks

in obese patients. However, the use of currently available anti-obesity drugs is

largely limited by poor long-term safety and a modest weight loss effect. Despite

substantial clinical and regulatory challenges, the early-stage obesity pipeline

remains robust, containing a high level of first-in-class innovation that has the

potential to be translated into effective and safe weight loss treatments.

Scope

Historically, the obesity market has suffered from long-term safety concerns and

modest efficacy with current treatments, both of which contribute to the low

prescription rate and limited widespread use.

- What are the main safety concerns that lead to significant challenges in gaining

drug approval in obesity?

- Why is sustainable weight loss difficult to achieve, and what is the implication

for future drug development?

Analysis reveals a high level of innovation and diversity in the pipeline, with 75

first-in-class programs identified to act on 60 unique molecular targets.

- What is the dominant target family across these first-in-class pipeline products?

- How well do they align with the underlying...